| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
779.67(B) |
| Last
Volume: |
1,985,020 |
Avg
Vol: |
3,278,293 |
| 52
Week Range: |
$434.7 - $815.06 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
345,365 |
1,215,365 |
2,860,521 |
5,816,033 |
| Total Sell Value |
$278,704,406 |
$886,389,786 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
2 |
2 |
5 |
6 |
| Total Sell Transactions |
6 |
18 |
46 |
86 |
| End Date |
2024-03-02 |
2023-11-30 |
2023-06-01 |
2022-06-01 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Oneill Myles |
SVP & Pres., Mfg. Operations |
• – – |
2020-03-04 |
4 |
AS |
$140.15 |
$3,503,750 |
I/I |
(25,000) |
8,469 |
|
17% |
|
| Zakrowski Donald A |
Chief Accounting Officer |
• – – |
2020-03-02 |
4 |
AS |
$128.00 |
$473,600 |
D/D |
(3,700) |
4,740 |
|
23% |
|
| Tai Jackson P |
Director |
– • – |
2020-02-18 |
4 |
A |
$141.01 |
$1,974 |
D/D |
14 |
58,095 |
|
- |
|
| Norton Johna |
Senior VP, Global Quality |
• – – |
2020-02-16 |
4 |
D |
$141.12 |
$4,798 |
I/I |
(34) |
128 |
|
- |
|
| Norton Johna |
Senior VP, Global Quality |
• – – |
2020-02-16 |
4 |
OE |
$0.00 |
$0 |
I/I |
97 |
162 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2020-02-11 |
4 |
A |
$144.25 |
$2,114,272 |
D/D |
14,657 |
122,072 |
|
- |
|
| Zakrowski Donald A |
Chief Accounting Officer |
• – – |
2020-02-11 |
4 |
A |
$144.25 |
$554,641 |
D/D |
3,845 |
8,440 |
|
- |
|
| Skovronsky Daniel |
SVP, CSO, and Pres. LRL |
• – – |
2020-02-11 |
4 |
A |
$144.25 |
$3,078,439 |
D/D |
21,341 |
97,159 |
|
- |
|
| Jonsson Patrik |
SVP and Pres., Lilly Bio-Meds |
• – – |
2020-02-11 |
4 |
A |
$144.25 |
$822,514 |
D/D |
5,702 |
25,079 |
|
- |
|
| Norton Johna |
Senior VP, Global Quality |
• – – |
2020-02-11 |
4 |
A |
$144.25 |
$256,477 |
D/D |
1,778 |
22,401 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2020-02-11 |
4 |
A |
$144.25 |
$806,069 |
D/D |
5,588 |
28,580 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2020-02-11 |
4 |
A |
$144.25 |
$11,191,781 |
D/D |
77,586 |
268,252 |
|
- |
|
| Mason Michael B |
Sr. VP & Pres., Lilly Diabetes |
• – – |
2020-02-11 |
4 |
A |
$144.25 |
$834,486 |
D/D |
5,785 |
15,035 |
|
- |
|
| Shah Aarti S. |
SVP & CIO |
• – – |
2020-02-11 |
4 |
A |
$144.25 |
$543,390 |
D/D |
3,767 |
21,087 |
|
- |
|
| White Anne E. |
SVP & Pres-Lilly Oncology |
• – – |
2020-02-11 |
4 |
A |
$144.25 |
$1,021,146 |
D/D |
7,079 |
29,122 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2020-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
18,322 |
56,646 |
|
- |
|
| Smiley Joshua L |
SVP and CFO |
• – – |
2020-02-11 |
4 |
A |
$144.25 |
$785,730 |
D/D |
5,447 |
36,971 |
|
- |
|
| Oneill Myles |
SVP & Pres., Mfg. Operations |
• – – |
2020-02-11 |
4 |
A |
$144.25 |
$627,343 |
D/D |
4,349 |
44,773 |
|
- |
|
| Lilly Endowment Inc |
10% Owner |
– – • |
2020-02-05 |
4 |
S |
$146.35 |
$29,321,808 |
D/D |
(200,000) |
113,520,304 |
|
-14% |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2020-02-01 |
4 |
D |
$139.64 |
$817,034 |
D/D |
(5,851) |
107,415 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2020-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,055 |
113,266 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2020-02-01 |
4 |
D |
$139.64 |
$4,341,268 |
D/D |
(31,089) |
195,666 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2020-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
69,350 |
226,755 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2020-02-01 |
4 |
D |
$139.64 |
$303,577 |
D/D |
(2,174) |
22,992 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2020-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,896 |
25,166 |
|
- |
|
1437 Records found
|
|
Page 24 of 58 |
|
|
3.53 (0.43%) 
